Wall Street brokerages expect Unum Therapeutics Inc (NASDAQ:UMRX) to post earnings of ($0.43) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Unum Therapeutics’ earnings. The highest EPS estimate is ($0.33) and the lowest is ($0.60). The business is scheduled to announce its next earnings results on Monday, February 11th.
On average, analysts expect that Unum Therapeutics will report full-year earnings of ($1.56) per share for the current fiscal year, with EPS estimates ranging from ($1.67) to ($1.44). For the next financial year, analysts forecast that the company will post earnings of ($1.55) per share, with EPS estimates ranging from ($1.76) to ($1.42). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Unum Therapeutics.
Unum Therapeutics (NASDAQ:UMRX) last released its quarterly earnings results on Monday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.01. Unum Therapeutics had a negative net margin of 404.34% and a negative return on equity of 382.71%. The company had revenue of $2.04 million during the quarter, compared to the consensus estimate of $2.29 million.
UMRX has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Unum Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 30th. Morgan Stanley increased their price target on shares of Unum Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, October 11th. Cowen restated a “hold” rating on shares of Unum Therapeutics in a research report on Monday, November 19th. Finally, Wedbush restated an “outperform” rating and set a $20.00 price objective on shares of Unum Therapeutics in a research report on Tuesday, September 18th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Unum Therapeutics has an average rating of “Buy” and an average target price of $20.67.
UMRX traded down $0.08 during midday trading on Thursday, reaching $6.32. The company’s stock had a trading volume of 49,914 shares, compared to its average volume of 261,451. Unum Therapeutics has a 1 year low of $6.26 and a 1 year high of $17.66.
In other news, insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction dated Thursday, October 25th. The shares were sold at an average price of $8.46, for a total value of $97,163.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders sold 34,455 shares of company stock valued at $320,776.
A number of large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in shares of Unum Therapeutics in the 3rd quarter valued at $150,000. Bank of New York Mellon Corp acquired a new position in Unum Therapeutics during the second quarter worth $177,000. Spark Investment Management LLC acquired a new position in Unum Therapeutics during the second quarter worth $186,000. Keybank National Association OH acquired a new position in Unum Therapeutics during the second quarter worth $195,000. Finally, JPMorgan Chase & Co. raised its position in shares of Unum Therapeutics by 2,782.4% in the third quarter. JPMorgan Chase & Co. now owns 20,753 shares of the company’s stock valued at $213,000 after buying an additional 20,033 shares during the last quarter. 51.81% of the stock is currently owned by institutional investors.
About Unum Therapeutics
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
Featured Article: How dollar cost averaging works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.